Overview and Scope
Mineral and bone disorder treatment refers to a treatment procedure recommended when there is an imbalance in the levels of calcium and phosphorus in the blood. The treatment regulates the levels of certain minerals and hormones in the blood to prevent bone and blood vessel damage.
Sizing and Forecast
The mineral and bone disorder treatment market size has grown strongly in recent years. It will grow from $3.06 billion in 2023 to $3.3 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to chronic kidney disease, aging population, rising awareness of mineral and bone disorders, increased availability of mineral and bone disorder treatments, rising disposable income levels.
The mineral and bone disorder treatment market size is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for quality of life treatments, growing demand for personalized medicine, government spending on healthcare, rising awareness of the importance of early diagnosis. Major trends in the forecast period include advancements in medical research, pharmaceutical developments, digital health, biologic therapies, telehealth and remote monitoring.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report
Segmentation & Regional Insights
The mineral and bone disorder treatment market covered in this report is segmented –
1) By Treatment: Diet; Nutrition; Medication; Supplements; Dialysis
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Top Major Players:
Pfizer Inc.
Merck & Co. Inc
Bayer AG
Novartis AG
Bristol-Myers Squibb Company
North America was the largest region in the mineral and bone disorder treatment market in 2023.
North America was the largest region in the mineral and bone disorder treatment market in 2023. The regions covered in mineral and bone disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12956&type=smp
Major Driver Impacting Market Growth
The increased elderly population is expected to boost the growth of the mineral and bone disorder treatment market going forward. The elderly population is a demographic group defined as individuals who are 65 years old or older. Elderly people experience muscle and bone mass loss, leading to weakness and reduced strength. Mineral and bone treatment can help prevent age-related changes in muscles, bones and joints, strengthen bones and delay the pace of bone loss. For instance, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, by 2030, the number of people aged 60 years or older is expected to increase from 1 billion in 2020 to 1.4 billion and 2.1 billion by 2050. The number of people aged 80 years or older is projected to be three times from 143 million in 2020 to 426 million in 2050. Therefore, the increased elderly population is driving the growth of the mineral and bone disorder treatment market.
Key Industry Players
Major players in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.
The mineral and bone disorder treatment market report table of contents includes:
1. Executive Summary
2. Mineral And Bone Disorder Treatment Market Characteristics
3. Mineral And Bone Disorder Treatment Market Trends And Strategies
4. Mineral And Bone Disorder Treatment Market – Macro Economic Scenario
5. Global Mineral And Bone Disorder Treatment Market Size and Growth
….
32. Global Mineral And Bone Disorder Treatment Market Competitive Benchmarking
33. Global Mineral And Bone Disorder Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Mineral And Bone Disorder Treatment Market
35.Mineral And Bone Disorder Treatment Market Future Outlook and Potential Analysis
36. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
